Lysine

Lysine

SCHEMBL14776740

NCCCC[C@H](N)C(=O)O.NCCCC[C@H](NC=O)C(=O)O

nearest known ligand 0.67

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ GSR P00390 1/20 0.67
▸ FOLH1 Q04609 1/20 0.47
▸ ARG2 P78540 4/20 0.43
▸ ARG1 P05089 3/20 0.43
▸ RNPEP Q9H4A4 1/20 0.42
▸ SLC6A5 Q9Y345 1/20 0.41
▸ NOD1 Q9Y239 1/20 0.40
▸ MMP2 P08253 1/20 0.40
▸ MMP9 P14780 1/20 0.40
▸ NOS3 P29474 2/20 0.39
▸ NOS1 P29475 2/20 0.39
▸ NOS2 P35228 2/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1168516 0.93 GSR (0.53) GSRFOLH1RNPEPSLC6A5MMP2
SCHEMBL28786641 0.93 GSR (0.53) GSRFOLH1RNPEPSLC6A5MMP2
SCHEMBL1168511 0.93 GSR (0.53) GSRFOLH1RNPEPSLC6A5MMP2
SCHEMBL10430391 0.88 FOLH1 (0.46) GSRFOLH1RNPEPSLC6A5MMP2
SCHEMBL27529124 0.88 FOLH1 (0.46) GSRFOLH1RNPEPSLC6A5MMP2
SCHEMBL6616072 0.88 FOLH1 (0.46) GSRFOLH1RNPEPSLC6A5MMP2
Acrylamide SCHEMBL28112667 0.84 FOLH1 (0.45) GSRFOLH1RNPEPSLC6A5MMP2
Lysine SCHEMBL27830975 0.84 GSR (0.95) GSRARG2ARG1RNPEPNOS3
Lysine SCHEMBL27830974 0.84 GSR (0.95) GSRARG2ARG1RNPEPNOS3
Lysine SCHEMBL1130394 0.83 GSR (0.71) GSRFOLH1ARG2ARG1RNPEP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3111953-A1 WHOLE-INACTIVATED INFLUENZA VIRUS AS AN ADJUVANT FOR PEPTIDE ANTIGENS De Staat der Nederlanden, vert. door de minister Van VWS, Ministerie van Volksgezondheid, Welzijn en Sport (NL) 2017-01-04 — — EP disclosed
US-9522962-B2 Peptides, conjugates and method for increasing immunogenicity of a vaccine ACADEMISCH ZIEKENHUIS LEIDEN H.O.D.N. LUMC (NL) 2016-12-20 — — US disclosed
EP-2547364-B1 Peptides, conjugates and method for increasing immunogenicity of a vaccine ACADEMISCH ZIEKENHUIS LEIDEN (NL) 2016-12-14 — — EP disclosed
US-20130071428-A1 PEPTIDES, CONJUGATES AND METHOD FOR INCREASING IMMUNOGENICITY OF A VACCINE STICHTING VOOR DE TECHNISCHE WETENSCHAPPEN (NL) 2013-03-21 — — US disclosed
Send feedback